摘要
氯吡格雷是目前广泛应用于临床的一种抗血小板药，已作为心肌梗死、缺血性卒中和周围血管病的二级预防用药。然而，氯吡格雷的抗血小板聚集效果存在显著的个体差异，很大一部分患者存在抵抗现象。氯吡格雷抵抗的机制尚不完全清楚，基因多态性是氯吡格雷抵抗的一个重要原因，包括ABCBl、CYP2C19、CYP3A4、CYP3A5、P2Y12和ITGB3等。
Clopidogrel is an antiplatelet drug widely used in clinical practice now. It has been used as the secondary prevention medication for myocardial infarction, ischemic stroke, and peripheral vascular disease. However, the anti-platelet aggregation effect of clopidogrel has significant individual differences. A large part of patients have clopidogel resistance phenomenon. The mechanism of clopidogel resistance is not fully understood. The genetic polymorphism is an important cause of clopidogrel resistance, including ABCB1, CYP2C19, CYP3A4, CYP3A5, P2Y12, and 1TGB3.
出处
《国际脑血管病杂志》
北大核心
2011年第11期841-844,共4页
International Journal of Cerebrovascular Diseases
基金
基金项目：国家自然科学基金（30870847）
